Indaptus Therapeutics’ Chief Scientific Officer Dr. Michael Newman to Present at the 10th Annual Innate Killer Summit

Rhea-AI Summary

Indaptus Therapeutics (Nasdaq: INDP) announced that Founder and Chief Scientific Officer Dr. Michael Newman will present at the 10th Annual Innate Killer Summit in San Diego on March 4, 2025.

Dr. Newman's presentation, titled "Employing Attenuated & Killed Gram-Negative Bacteria to Induce NK-Mediated Anti-Tumor Immunity," will cover:

• The science behind Indaptus' Decoy platform, a multi-immune receptor agonist designed to trigger broad immune activation against tumors
• The Company's "Pulse-Prime" approach for safe and effective anti-tumor activity in pre-clinical models
• Clinical data from the ongoing Phase 1 trial of Decoy20 in advanced solid tumors

CEO Jeffrey Meckler emphasized that their Decoy platform is designed to harness multiple arms of the immune system, including Natural Killer (NK) cells, to combat cancer. The summit, taking place March 3-5, 2025, brings together experts to advance NK-based therapeutic approaches in oncology.

Positive

• Indaptus Therapeutics is presenting at a premier conference focused on innate immune strategies in oncology
• The company has an ongoing Phase 1 clinical trial for their Decoy20 treatment in advanced solid tumors
• Their technology activates both innate and adaptive immune responses against tumors
• The Decoy platform represents a novel approach to cancer immunotherapy using bacterial components

Negative

• No specific efficacy results from the Phase 1 trial were disclosed in the press release
• The company is still in early clinical stages with their lead candidate
• No information was provided about the timeline for potential regulatory approvals
• Competition in the immuno-oncology space is intense with many established players

NEW YORK, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a clinical-stage biotechnology company dedicated to developing novel treatments for cancer and viral infections, today announced that Michael Newman, Founder and Chief Scientific Officer, will present at the 10th Annual Innate Killer Summit, taking place from March 3-5, 2025, in San Diego, California.

Dr. Newman will deliver a scientific presentation on Tuesday, March 4, 2025, titled, “Employing Attenuated & Killed Gram-Negative Bacteria to Induce NK-Mediated Anti-Tumor Immunity.”

In this presentation, Dr. Newman will discuss:

• The science behind Indaptus’ Decoy platform, a multi-immune receptor agonist designed to trigger broad innate and adaptive immune activation against tumors.
• How the Company’s “Pulse-Prime” approach supports safe and effective anti-tumor activity in pre-clinical models, including the role of Natural Killer (NK) cells.
• Clinical data from Indaptus’ ongoing Phase 1 trial evaluating Decoy20 in advanced solid tumors.
  

“We are excited to share our progress at this premier conference focused on innate immune strategies in oncology,” said Jeffrey Meckler, CEO of Indaptus Therapeutics. “Our Decoy platform is designed to safely and effectively harness multiple arms of the immune system — including NK cells — to combat cancer. Dr. Newman’s presentation will highlight how our approach aligns with the next generation of immune-based therapies.”

The 10th Annual Innate Killer Summit brings together experts in the NK space to advance the development of NK engager, NK bispecific, cell therapy and cytokine-based approaches to the clinic.

For more information about the 10th Annual Innate Killer Summit, visit: https://innate-killer.com/.

About Indaptus Therapeutics

Indaptus Therapeutics has evolved from more than a century of immunotherapy advances. The Company’s novel approach is based on the hypothesis that efficient activation of both innate and adaptive immune cells and pathways and associated anti-tumor and anti-viral immune responses will require a multi-targeted package of immune system-activating signals that can be administered safely intravenously (i.v.). Indaptus’ patented technology is composed of single strains of attenuated and killed, non-pathogenic, Gram-negative bacteria producing a multiple Toll-like receptor (TLR), Nucleotide oligomerization domain (NOD)-like receptor (NLR) and Stimulator of interferon genes (STING) agonist Decoy platform. The product candidates are designed to have reduced i.v. toxicity, but largely uncompromised ability to prime or activate many of the cells and pathways of innate and adaptive immunity. Decoy product candidates represent an antigen-agnostic technology that have produced single-agent activity against metastatic pancreatic and orthotopic colorectal carcinomas, single agent eradication of established antigen-expressing breast carcinoma, as well as combination-mediated eradication of established hepatocellular carcinomas, pancreatic and non-Hodgkin’s lymphomas in standard pre-clinical models, including syngeneic mouse tumors and human tumor xenografts. In pre-clinical studies tumor eradication was observed with Decoy product candidates in combination with anti-PD-1 checkpoint therapy, low-dose chemotherapy, a non-steroidal anti-inflammatory drug, or an approved, targeted antibody. Combination-based tumor eradication in pre-clinical models produced innate and adaptive immunological memory, involved activation of both innate and adaptive immune cells, and was associated with induction of innate and adaptive immune pathways in tumors after only one i.v. dose of Decoy product candidate, with associated “cold” to “hot” tumor inflammation signature transition. IND-enabling, nonclinical toxicology studies demonstrated i.v. administration without sustained induction of hallmark biomarkers of cytokine release syndromes, possibly due to passive targeting to liver, spleen, and tumor, followed by rapid elimination of the product candidate. Indaptus’ Decoy product candidates have also produced meaningful single agent activity against chronic hepatitis B virus (HBV) and chronic human immunodeficiency virus (HIV) infections in pre-clinical models.

For more information, visit www.indaptusrx.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act. These include statements regarding management’s expectations, beliefs and intentions regarding, among other things, our research and development plans. Forward-looking statements can be identified by the use of forward-looking words such as “believe”, “expect”, “intend”, “plan”, “may”, “should”, “could”, “might”, “seek”, “target”, “will”, “project”, “forecast”, “continue” or “anticipate” or their negatives or variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical matters. Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to risks and uncertainties that could cause our actual results to differ materially from any future results expressed or implied by the forward-looking statements. Many factors could cause actual activities or results to differ materially from the activities and results anticipated in forward-looking statements, including, but not limited to the following: our limited operating history; conditions and events that raise substantial doubt regarding our ability to continue as going concern; the need for, and our ability to raise, additional capital given our lack of current cash flow; our clinical and preclinical development, which involves a lengthy and expensive process with an uncertain outcome; our incurrence of significant research and development expenses and other operating expenses, which may make it difficult for us to attain profitability; our pursuit of a limited number of research programs, product candidates and specific indications and failure to capitalize on product candidates or indications that may be more profitable or have a greater likelihood of success; our ability to obtain and maintain regulatory approval of any product candidate; the market acceptance of our product candidates; our reliance on third parties to conduct our preclinical studies and clinical trials and perform other tasks; our reliance on third parties for the manufacture of our product candidates during clinical development; our ability to successfully commercialize Decoy20 or any future product candidates; our ability to obtain or maintain coverage and adequate reimbursement for our products; the impact of legislation and healthcare reform measures on our ability to obtain marketing approval for and commercialize Decoy20 and any future product candidates; product candidates of our competitors that may be approved faster, marketed more effectively, and better tolerated than our product candidates; our ability to adequately protect our proprietary or licensed technology in the marketplace; the impact of, and costs of complying with healthcare laws and regulations, and our failure to comply with such laws and regulations; information technology system failures, cyberattacks or deficiencies in our cybersecurity; and unfavorable global economic conditions. These and other important factors discussed under the caption “Risk Factors” included in our Quarterly Report on Form 10-Q for the quarter ended September 30, 2024 filed with the SEC on November 12, 2024, our most recent Annual Report on Form 10-K filed with the SEC on March 13, 2024, and our other filings with the SEC, could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. All forward-looking statements speak only as of the date of this press release and are expressly qualified in their entirety by the cautionary statements included in this press release. We undertake no obligation to update or revise forward-looking statements to reflect events or circumstances that arise after the date made or to reflect the occurrence of unanticipated events, except as required by applicable law.

Contact: investors@indaptusrx.com

Investor Relations Contact:
CORE IR
Louie Toma
louie@coreir.com

FAQ

What is Indaptus Therapeutics (INDP) presenting at the 10th Annual Innate Killer Summit?

Indaptus Therapeutics' CSO Dr. Michael Newman will present "Employing Attenuated & Killed Gram-Negative Bacteria to Induce NK-Mediated Anti-Tumor Immunity" on March 4, 2025, discussing the Decoy platform technology, the Pulse-Prime approach, and clinical data from their Phase 1 trial of Decoy20 in advanced solid tumors.

When and where will Indaptus Therapeutics (INDP) present at the Innate Killer Summit 2025?

Indaptus Therapeutics will present on Tuesday, March 4, 2025, at the 10th Annual Innate Killer Summit taking place from March 3-5, 2025, in San Diego, California.

What is the Decoy platform technology being developed by Indaptus Therapeutics (INDP)?

The Decoy platform is a multi-immune receptor agonist designed to trigger broad innate and adaptive immune activation against tumors. It works by safely harnessing multiple arms of the immune system, including Natural Killer (NK) cells, to combat cancer.

What clinical trials is Indaptus Therapeutics (INDP) currently conducting?

Indaptus Therapeutics is currently conducting a Phase 1 clinical trial evaluating Decoy20 in patients with advanced solid tumors. Data from this ongoing trial will be presented at the 10th Annual Innate Killer Summit.

How does Indaptus Therapeutics' (INDP) Pulse-Prime approach work against tumors?

Indaptus Therapeutics' Pulse-Prime approach supports safe and effective anti-tumor activity by leveraging attenuated and killed Gram-negative bacteria to induce NK-mediated anti-tumor immunity, as demonstrated in pre-clinical models.

What therapeutic areas is Indaptus Therapeutics (INDP) focusing on with their technology?

Indaptus Therapeutics is a clinical-stage biotechnology company dedicated to developing novel treatments for cancer and viral infections using their proprietary immune-activating technology platforms.